| A comparative analysis of important public clinical trial registries, and a proposal for an interim ideal one N Venugopal, G Saberwal PLoS One 16 (5), e0251191, 2021 | 25 | 2021 |
| The primary cilium dampens proliferative signaling and represses a G2/M transcriptional network in quiescent myoblasts N Venugopal, A Ghosh, H Gala, A Aloysius, N Vyas, J Dhawan BMC molecular and cell biology 21, 1-19, 2020 | 19 | 2020 |
| Mimicking muscle stem cell quiescence in culture: methods for synchronization in reversible arrest R Arora, M Rumman, N Venugopal, H Gala, J Dhawan Muscle stem cells: Methods and protocols, 283-302, 2017 | 14 | 2017 |
| A transcriptionally repressed quiescence program is associated with paused RNA polymerase II and is poised for cell cycle re-entry HP Gala, D Saha, N Venugopal, A Aloysius, G Purohit, J Dhawan Journal of Cell Science 135 (15), jcs259789, 2022 | 5 | 2022 |
| RNA polymerase II pausing regulates a quiescence-dependent transcriptional program, priming cells for cell cycle reentry HP Gala, D Saha, N Venugopal, A Aloysius, J Dhawan bioRxiv, 250910, 2018 | 4 | 2018 |
| Building cross-border collaborations to increase diversity and accelerate rare disease drug development–meeting report from the inaugural IndoUSrare Annual Conference 2021 HK Khera, N Venugopal, RT Karur, R Mishra, RV Kartha, HK Rajasimha Therapeutic Advances in Rare Disease 3, 26330040221133124, 2022 | 1 | 2022 |
| Primary cilia in myoblasts: a role in quiescence N Venugopal, J Dhawan Cilia 4 (Suppl 1), P79, 2015 | 1 | 2015 |
| Review of methods for estimating the prevalence of rare diseases N Venugopal, G Naik, K Jayanna, A Mohapatra, FJ Sasinowski, ... | | 2024 |
| Impact of COVID-19 on rare disease research and clinical development: a global perspective N Venugopal, RV Kartha, A Baranova, R Harsha K. Translational Genomics 2 (e1-8), 2021 | | 2021 |
